Transthyretin cardiac amyloidosis in Saudi Arabia and the Middle East: insights, projected prevalence and practical applications

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Omar Ahmad¹  Talal Alzahrani²  Dania Mohty³  Bahaa Fadel³  Islam Alayary⁴  Thibaud Damy⁵  Mohamed H. Omer⁶ 

[1] College of Medicine, Al Faisal University, Riyadh, Saudi Arabia;Department of Medicine, College of Medicine, Taibah University, Medina, Saudi Arabia;Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia;College of Medicine, Al Faisal University, Riyadh, Saudi Arabia;Rare Diseases Medical Affairs, Pfizer Inc., Jeddah, Saudi Arabia;Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France;School of Medicine, Cardiff University, Cardiff, United Kingdom;

关键词: cardiac amyloidosis;    transthyretin;    epidemiology;    prevalence;    incidence;    Saudi Arabia;    Middle East;   

DOI  :  10.3389/fcvm.2023.1265681

 received in 2023-07-23, accepted in 2023-10-16,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
© 2023 Mohty, Omer, Ahmad, Alayary, Alzahrani, Damy and Fadel.